Novo Nordisk A/S is a global healthcare company focused on the discovery, development, manufacturing, and marketing of pharmaceutical products for serious chronic diseases. The company operates through two business segments: Obesity and Diabetes care, and Rare disease. Its product portfolio includes glucagon-like-peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes, modern and human insulins, growth hormone, and haemophilia treatments. Key products include Ozempic, Saxenda, Wegovy, and Wegovy Pill. Novo Nordisk markets its products in the United States, China, Canada, Japan, and major European countries, as well as in other regions including Europe, Canada, Latin America, the Middle East, Africa, Japan, Korea, Oceania, Southeast Asia, and Mainland China. The company was formed in 1989 by the merger of Nordisk Gentofte A/S and Novo Industri A/S, with business activities originating in 1923 and 1925. In December 2025, Novo Nordisk acquired Akero Therapeutics Inc., a clinical-stage company developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage novonordisk.com
Sector Healthcare IR page novonordisk.com/investors
Tags
obesity, diabetes, rare disease, glp-1 receptor agonists, insulin, growth hormone, haemophilia, metabolic disorders, pharmaceuticals, Ozempic, Saxenda, Wegovy, Wegovy Pill, Akero Therapeutics, efruxifermin, Novo Nordisk Foundation
Press page novonordisk.com/news-and-media/news-and-ir-materials

Metrics

Valuation  
Market cap DKK 168.472B
Market cap (USD) $ 24.722B
P/E 10.84
PEG 0.48
P/BV 5.72
P/S 3.59
P/OCF 9.31
P/FCF 18.81
Dividend yield 0.01%
Turnover / mcap —
Returns  
ROE 60.7%
ROI 31.5%
ROIC 30.8%
Profit margin 33.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 22.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 67.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 140
Quality score 47.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2014
Revenue 309.064B 290.403B 232.261B 176.954B 140.8B 126.946B 18.477B 0
Net profit 102.434B 100.988B 83.683B 55.525B 47.757B 42.138B 6.28B —
Free cash flow 58.962B 73.804B 83.102B 66.741B 48.665B 46.126B — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2014
Share price 323.23 584.3 708.38 999.9 706.58 444.88 49.73 —
Price performance 12m -0.41 -0.17 -0.24 0.21 0.6 0.21 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (DKK) 14.2B 15.5B 17.8B 24B 32.4B 48.1B 52B
↳ 5y CAGR +27.6% +27.5%
Reported Feb 2, 2022 Feb 2, 2022 Feb 2, 2022 Feb 1, 2023 Jan 31, 2024 Feb 5, 2025 Feb 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Novo Nordisk A/S – Share repurchase programme Bull 2 Bear 0 Capital return

Bagsværd, Denmark, 16 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 9 November, the following transactions have been made:

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 27,845,000 8,008,013,722

Accumulated under the programme 28,975,000 8,318,073,280

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Novo Nordisk A/S – Share repurchase programme Bull 2 Bear 0 Capital return

Bagsværd, Denmark, 9 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 3 November, the following transactions have been made:

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 26,955,000 7,764,364,812

Accumulated under the programme 27,845,000 8,008,013,722

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 56,644,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.3% of the share capital.

  • In a real-world study, semaglutide 2.4 mg once-weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months
  • Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures
  • Additional real-world data from a separate analysis found people initiating semaglutide 2.4 mg had greater one-year reductions in liver enzymes and weight, plus a larger HbA1c decrease, versus those not initiating treatment with semaglutide 2.4 mg

Plainsboro, New Jersey, US and Bagsværd, Denmark, 6 November 2026 - Novo Nordisk today announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once-weekly injection use versus those not initiating treatment with semaglutide 2.4 mg and liver and cardiometabolic outcomes in adults with metabolic dysfunction-associated steatohepatitis (MASH). Results were presented at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® 2026 in Denver, Colorado.

“Living with MASH can be incredibly challenging because the disease may progress without clear symptoms, making it even more important to understand the clinical data about how a treatment may help their disease,” said Michelle Skinner Moore, PhD, MBA, Vice President, Medical Affairs at Novo. “The findings from PLATINUM-Truveta and RHODIUM offer insights into real-world results for patients treated for MASH and help to inform providers.”  

PLATINUM-Truveta included 2,873 adults with MASH who initiated treatment with semaglutide 2.4 mg and 2,285 adults with MASH who initiated treatment with resmetirom. Key adjusted outcomes at three and six months are summarized below.1

Table 1. Changes in liver enzymes & cardiometabolic markers from baseline to 3 months & 6 months from PLATINUM-Truveta

Time point and measure Semaglutide 2.4 mg Resmetirom Between-group P value
Three months
AST (U/L) -6.7 -1.9 <0.001
ALT (U/L) -8.7 -4.8 0.077
HbA****1c (percentage points) -0.29 +0.03 <0.001
Body weight (lb) -10.5 -1.5 <0.001
Triglycerides -27.9 -26.0 0.83
HDL -2.0 -0.7 0.34
LDL -10.3 -20.7 <0.05
Platelets +6.8 +2.7 0.48
Six months
AST (U/L) -10.4 -4.5 <0.001
ALT (U/L) -14.8 -11.6 0.20
HbA****1c (percentage points) -0.38 -0.08 <0.001
Body weight (lb) -18.9 -5.6 <0.001
Triglycerides -29.4 -30.5 0.91
HDL +0.3 -1.4 0.29
LDL -13.7 -29.1 <0.001
Platelets +7.8 -4.4 0.022

ALT = alanine aminotransferase; AST = aspartate aminotransferase; HDL = high-density lipoprotein; LDL = low-density lipoprotein. Values are adjusted mean changes from baseline. Negative values indicate reductions. Values presented are weighted means without additional covariate adjustment.

“Every patient with MASH has different metabolic needs,” said Dr. Eric Lawitz, Texas Liver Institute, and University of Texas Health San Antonio. “This real-world analysis offers insights that may help clinicians inform treatment decisions for people living with MASH.”

RHODIUM-2 compared 2,479 adults with MASH who initiated semaglutide 2.4 mg with 70,702 adults with MASH who did not initiate semaglutide. Key adjusted outcomes at 12 months are summarized below.2

Table 2. Change in liver enzymes and cardiometabolic markers from baseline to 12 months from RHODIUM-2*

Measure Semaglutide 2.4 mg initiators No semaglutide initiation Adjusted between-group difference P value
ALT (U/L) -14.0 -3.8 -10.5 <0.01
AST (U/L) -9.1 -1.8 -7.3 0.001
Body weight (lb) -30.7 -2.4 -28.4 <0.001
HbA1c (percentage points)* -0.46 -0.09 NR NR
Exploratory endpoints
Elevated ALT subgroup — ALT (U/L) -24.3 -10.7 -13.7 0.002
Elevated ALT subgroup — AST (U/L) -14.2 -5.3 -8.9 0.002

Values are adjusted mean changes from baseline, except HbA1c. Negative values indicate reductions. NR = not reported. Elevated ALT defined as ALT > 25 in women and ALT > 35 in men.
*The results are paired baseline and 12-month data.

Both studies were retrospective and observational. Treatment was not randomized, the groups differed in baseline characteristics, and results were based on patients with available follow-up measurements who met treatment-persistence criteria.

Real-world study data can provide valuable insights into how treatments work outside of controlled clinical trial settings. Real-world data analyses also have several limitations; while associations can be demonstrated, causal relationships cannot be definitively established. Results may reflect potential unmeasured confounding, the relatively recent approval of both treatments limited follow-up duration, and electronic medical record data may be subject to coding inaccuracies.

About PLATINUM-Truveta
PLATINUM-Truveta was an observational, retrospective cohort study that used de-identified electronic medical record data from the Truveta database across 30 US health systems from June 2021 through March 2026. Adults with MASH who initiated semaglutide 2.4 mg once weekly injection (n=2,873) or resmetirom (n=2,285) were included. Changes from baseline in ALT, AST, body weight, HbA1c, platelets, triglycerides, HDL, and LDL were assessed at three and six months. Patients with prior use of semaglutide or resmetirom, cirrhosis or other chronic liver diseases were excluded, and treatment persistence was required at each time point. To reduce confounding, generalized estimating equations with inverse probability of treatment weighting were applied. Patients in the semaglutide group were defined as having MASH if they had one or more claim with a diagnosis code for MASH (ICD-10 CM K75.81) in the 12 month period before index date.1

About RHODIUM-2
RHODIUM-2 was an observational, retrospective study that used de-identified electronic medical record data from the Truveta database across more than 30 US health systems from June 2021 through March 2026. Adults with MASH were grouped according to whether they initiated semaglutide 2.4 mg once weekly injection (n=2,479) or did not initiate semaglutide (n=70,702). Changes from baseline in ALT, AST, body weight, and HbA1c were assessed at 3, 6, and 12 months. Patients with cirrhosis or other liver disease etiologies and those treated with GLP-1 receptor agonists or resmetirom within six months before start of first treatment were excluded. To control for confounding, generalized estimating equations to account for within patient correlation, and inverse probability of treatment weighting was applied.2

About metabolic dysfunction-associated steatohepatitis (MASH)
MASH is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not managed properly.3 More than 250 million people live with MASH,4 and the number of individuals in advanced stages of the disease is expected to increase over 160% from 2015 to 2030.5 Of those living with overweight or obesity, more than one in three also have MASH.6 And of those currently living with MASH, more than 40% have type 2 diabetes, and more than 8 in 10 also live with obesity.7 People living with MASH often have many other health-related comorbidities,8 such as cardiovascular disease, which is the leading cause of death in people with MASH.9,10

MASH is largely a silent disease due to few and unspecific symptoms in its early stages,3 where nearly 90% of people with MASH remain undiagnosed.11 Once MASH progresses to late stages, there is increased mortality and morbidity, including potential for cirrhosis, liver cancer, and need for liver transplant.12

About semaglutide 2.4 mg once weekly injection in metabolic dysfunction-associated steatohepatitis (MASH)
Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate-to-advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity.13 This accelerated approval is based on improvement of MASH and liver scarring (fibrosis).13 Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.13 Novo is investigating semaglutide 2.4 mg in the ongoing ESSENCE phase 3 trial, evaluating the effect of once weekly subcutaneous semaglutide 2.4 mg in adults with MASH with moderate-to-advanced liver scarring (fibrosis) (consistent with stage F2 or F3†).13

It is important to note that semaglutide 2.4 mg injection has a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The most common side effects of semaglutide include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.13

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. In the United States, Novo has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people. For more information, visit novonordisk.com and novonordisk-us.com and follow us on Instagram , LinkedIn , TikTok , Facebook , X and YouTube . 

Prompts

Novo Nordisk A/S (ticker NVO), listed in United States.

Company History

Date Change Detail
Sep 14, 2023 Acquired Acquired BIOCORP PRODUCTION (CIK 969500TKUAME6031UQ32). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Novo Nordisk A/S

ETF Weight in ETF Shares Market value As of
NVOH 96.87% 84,261 $ 4.039M Jun 30, 2026
OZEM 10.92% 149,897 $ 6.101M Nov 17, 2026
HRTS 4.79% 58,624 $ 2.664M Aug 31, 2026
MTRA 2.41% 71,416 $ 3.37M Jul 31, 2026
DTAN 2.23% 11,947 $ 484.724K Nov 17, 2026
IVSI 2.16% 3,545 $ 170.486K Jun 30, 2026
ACEP 2.15% 52,041 $ 2.12M Nov 18, 2026
DVGR 2.15% 8,857 $ 360K Nov 18, 2026
CGXU 2.12% 3,242,374 $ 136.048M Nov 16, 2026
IVAL 2.08% 113,068 $ 4.59M Nov 18, 2026
TINS 2.01% 2,444 $ 117.602K Jun 30, 2026
ATFV 1.90% 78,410 $ 3.759M Jun 30, 2026
CVGD 1.85% 54,442 $ 2.563M Jul 31, 2026
SAGP 1.72% 27,346 $ 1.316M Jun 30, 2026
WCMI 1.70% 859,837 $ 35.769M Nov 16, 2026
AQEC 1.67% 200,297 $ 9.602M Jun 30, 2026
JDVI 1.61% 237,514 $ 11.429M Jun 30, 2026
PGRI 1.45% 2,081 $ 99.763K Jun 30, 2026
UMMA 1.26% 82,126 $ 3.732M Aug 31, 2026
CNEQ 1.08% 165,556 $ 7.937M Jun 30, 2026
DIHP 1.04% 1,679,994 $ 68.578M Nov 12, 2026
CGIE 0.99% 576,507 $ 24.19M Nov 16, 2026
PSTR 0.85% 12,642 $ 573.062K Aug 31, 2026
APIE 0.84% 213,302 $ 9.669M Aug 31, 2026
CGDG 0.71% 1,010,863 $ 42.415M Nov 16, 2026
NTSI 0.70% 72,389 $ 3.483M Jun 30, 2026
IGGY 0.69% 678 $ 30.806K Aug 31, 2026
TOUS 0.65% 216,547 $ 10.243M Jul 31, 2026
CGGO 0.60% 1,658,303 $ 69.581M Nov 16, 2026
TIER 0.55% 4,059 $ 191.997K Jul 31, 2026
RINT 0.54% 15,766 $ 758.216K Jun 30, 2026
JHID 0.54% 1,224 $ 58.897K Jun 30, 2026
VDI 0.51% 1,763 $ 83.363K Jul 31, 2026
RCGE 0.51% 12,370 $ 500K Nov 18, 2026
QUIZ 0.49% 9,927 $ 451.08K Aug 31, 2026
AVIV 0.47% 236,531 $ 9.84M Nov 16, 2026
GOP 0.43% 9,056 $ 376.73K Nov 17, 2026
DFSI 0.42% 120,450 $ 4.917M Nov 12, 2026
RFDI 0.41% 14,330 $ 677.591K Jul 31, 2026
CGIC 0.40% 242,260 $ 10.165M Nov 16, 2026
MFSI 0.36% 97,611 $ 4.435M Aug 31, 2026
AVDE 0.31% 1,466,872 $ 61.022M Nov 16, 2026
DFAI 0.30% 1,341,738 $ 54.762M Nov 12, 2026
RGLO 0.29% 20,182 $ 970.59K Jun 30, 2026
AVSD 0.27% 24,140 $ 1.004M Nov 16, 2026
DXIV 0.23% 13,346 $ 544.387K Nov 12, 2026
DFIC 0.19% 721,353 $ 29.437M Nov 12, 2026
CGNG 0.19% 130,441 $ 5.473M Nov 16, 2026
FENI 0.15% 313,722 $ 15.084M Jun 30, 2026
GEW 0.14% 4,572 $ 207.733K Aug 31, 2026
NBIE 0.12% 6,588 $ 299.331K Aug 31, 2026
JSTC 0.09% 6,452 $ 270.973K Nov 17, 2026
IQSZ 0.07% 2,547 $ 120.204K Jul 31, 2026
DFAX 0.06% 191,383 $ 7.804M Nov 12, 2026
PINK 0.00% 351 $ 14.286K Nov 17, 2026
NPFE 0.00% 351 $ 16.525K Jul 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
NVO canonical Common share — US nyse 37.91 USD 2026-09-30
NOVOB Common share B DK nordic — —